Roche Holdings, Inc. Announces Final Results of its Debt Tender Offer

07 Oct, 2015, 10:37 ET from Roche Holdings, Inc.

BASEL, Switzerland, Oct. 7, 2015 /PRNewswire/ -- Roche Holdings, Inc. (the "Offeror") announced today the final results of its previously announced tender offer (the "Offer") to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $1.2 billion (the "Maximum Tender Amount") the 7.00% Notes due 2039 issued by the Offeror and guaranteed by Roche Holding Ltd (the "Company") (CUSIP Nos. 771196 AU6 and U75000 AN6), the 6.00% Notes due 2019 issued by the Offeror and guaranteed by the Company (CUSIP Nos. 771196 AS1 and U75000 AM8) and the 5.25% Senior Notes due 2035 issued by the Offeror's subsidiary Genentech, Inc. ("Genentech") (CUSIP No. 368710 AC3) (collectively, the "Securities").

As previously announced, the Offeror accepted for purchase $336,813,000 aggregate principal amount of the 7.00% Notes due 2039, $538,039,000 aggregate principal amount of the 6.00% Notes due 2019 and $25,025,000 aggregate principal amount of the 5.25% Senior Notes due 2035 that were validly tendered and not validly withdrawn on or prior to 5:00 p.m., New York City time, on September 22, 2015 (the "Early Tender Date"). Settlement in respect of these Securities occurred on September 24, 2015.

Following the Early Tender Date and on or prior to 11:59 p.m., New York City time, on October 6, 2015 (the "Expiration Date"), an additional $275,000 aggregate principal amount of the 7.00% Notes due 2039 and $5,442,000 aggregate principal amount of the 6.00% Notes due 2019 were validly tendered and accepted for purchase. Payment for the Securities that were validly tendered after the Early Tender Date but on or prior to the Expiration Date and accepted for purchase is expected to be made tomorrow October 8, 2015.    

The aggregate amount of Securities validly tendered on or prior to the Expiration Date, including the Securities validly tendered and not validly withdrawn on or prior to the Early Tender Date, is set out below:

Title of Security

Issuer

CUSIP and ISIN Numbers

Principal
Amount Outstanding(1)

Principal Amount Tendered

Acceptance Priority Level

Early Tender Premium (per $1,000)

Total Consideration (per $1,000)(2)

Tender Offer Consideration (per $1,000)










7.00% Notes due 2039

Roche Holdings, Inc.

771196 AU6 U75000 AN6

US771196AU61

USU75000AN65

$1,606,075,000

$337,088,000

1

$50.00

$1,453.31

$1,403.31










6.00% Notes due 2019

Roche Holdings, Inc.

771196 AS1

U75000 AM8

US771196 AS16

USU75000 AM82

$2,000,000,000

$543,481,000

2

$50.00

$1,141.33

$1,091.33










5.25% Senior Notes due 2035

Genentech, Inc.

368710 AC3

US368710 AC32

$350,016,000

$25,025,000

3

$50.00

$1,184.88

$1,134.88










(1) As of the commencement of the Offer.










(2) Inclusive of the Early Tender Premium.





 

 

 

The Offer was made upon and was subject to the terms and conditions set forth in the Offer to Purchase dated September 9, 2015, as amended by the Offeror's press release dated September 23, 2015 announcing an increase in the Maximum Tender Amount to $1.2 billion.

Citigroup Global Markets Inc. acted as Dealer Manager for the Offer. The depositary and information agent for the Offer was Global Bondholder Services Corporation.  Questions regarding the Offer should be directed to Citigroup Global Markets Inc., Liability Management Group, at (800) 558-3745 (toll-free), (212) 723-6106 (collect) or +44 20 7986 8969 (Europe).

About the Roche Group

The Company is the parent company of the Offeror and Genentech. The Company and its consolidated subsidiaries, including the Offeror and Genentech, are referred to hereinafter as the "Roche Group".

Founded in 1896 in Basel, Switzerland, the Company is the parent company of an international research-focused healthcare group which operates in more than 150 countries and employs more than 88,500 people worldwide.  The Roche Group's products and services address the prevention, diagnosis, treatment and monitoring of diseases.

SOURCE Roche Holdings, Inc.